Update to the Biosimilar Preferred Drug List-Correction
On December 1, 2023, the Office of MaineCare Services (OMS) notified providers of the changes to the Biosimilar Preferred Drug List effective January 4, 2024. The notice sent on December 1, 2023, inadvertently omitted the drug class Rituximab.